0001193125-22-158629.txt : 20220524 0001193125-22-158629.hdr.sgml : 20220524 20220524170110 ACCESSION NUMBER: 0001193125-22-158629 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220518 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20220524 DATE AS OF CHANGE: 20220524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NGM BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0001426332 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38853 FILM NUMBER: 22957875 BUSINESS ADDRESS: STREET 1: 333 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-243-5555 MAIL ADDRESS: STREET 1: 333 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 d311234d8k.htm 8-K 8-K
NGM BIOPHARMACEUTICALS INC false 0001426332 0001426332 2022-05-18 2022-05-18

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 18, 2022

 

 

NGM Biopharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-38853   26-1679911

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

333 Oyster Point Boulevard

South San Francisco, California

  94080
(Address of Principal Executive Offices)   (Zip Code)

(650) 243-5555

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   NGM   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.07

Submission of Matters to a Vote of Security Holders.

On May 18, 2022, NGM Biopharmaceuticals, Inc. (the “Company”) held its 2022 annual meeting of stockholders (the “Annual Meeting”). The following is a brief description of each matter voted on at the Annual Meeting, as well as the votes cast with respect to each matter, and if applicable, the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter can be found in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 6, 2022.

 

1.

Election of Directors

 

Director Name

   Votes For      Votes
Withheld
     Broker
Non-Votes
 

David V. Goeddel, Ph.D.

     53,943,473        10,333,414        6,215,944  

Suzanne Sawochka Hooper

     55,578,629        8,698,258        6,215,944  

David J. Woodhouse, Ph.D.

     54,839,003        9,437,884        6,215,944  

The Class III director nominees were elected to hold office until the Company’s 2025 annual meeting of stockholders and until their successors are duly elected and qualified.

 

2.

Advisory Vote on Executive Compensation

 

Votes For    Votes Against    Abstentions    Broker Non-Votes
48,944,032    15,300,203    32,652    6,215,944

The stockholders of the Company approved, on an advisory basis, the compensation of the Company’s named executive officers.

 

3.

Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation

 

One Year    Two Years    Three Years    Abstentions
60,967,819    1,529    3,302,480    5,059

The stockholders of the Company expressed their preference, on an advisory basis, to have a non-binding vote on the compensation of the Company’s named executive officers every year.

 

4.

Ratification of Selection of Independent Registered Public Accounting Firm

 

Firm

   Votes For    Votes Against    Abstentions

Ernst & Young LLP

   70,462,410    29,817    604

The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    NGM Biopharmaceuticals, Inc.  
Dated: May 24, 2022     By:  

/s/ Valerie Pierce

 
      Valerie Pierce  
      Secretary, Senior Vice President, General Counsel and Chief Compliance Officer  
EX-101.SCH 2 ngm-20220518.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 ngm-20220518_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 ngm-20220518_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 18, 2022
Cover [Abstract]  
Entity Registrant Name NGM BIOPHARMACEUTICALS INC
Amendment Flag false
Entity Central Index Key 0001426332
Document Type 8-K
Document Period End Date May 18, 2022
Entity Incorporation State Country Code DE
Entity File Number 001-38853
Entity Tax Identification Number 26-1679911
Entity Address, Address Line One 333 Oyster Point Boulevard
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 243-5555
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol NGM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 d311234d8k_htm.xml IDEA: XBRL DOCUMENT 0001426332 2022-05-18 2022-05-18 NGM BIOPHARMACEUTICALS INC false 0001426332 8-K 2022-05-18 DE 001-38853 26-1679911 333 Oyster Point Boulevard South San Francisco CA 94080 (650) 243-5555 false false false false Common Stock, par value $0.001 per share NGM NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d311234d8k.htm ngm-20220518.xsd ngm-20220518_lab.xml ngm-20220518_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d311234d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d311234d8k.htm" ] }, "labelLink": { "local": [ "ngm-20220518_lab.xml" ] }, "presentationLink": { "local": [ "ngm-20220518_pre.xml" ] }, "schema": { "local": [ "ngm-20220518.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ngm", "nsuri": "http://www.ngmbio.com/20220518", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d311234d8k.htm", "contextRef": "duration_2022-05-18_to_2022-05-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d311234d8k.htm", "contextRef": "duration_2022-05-18_to_2022-05-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ngmbio.com//20220518/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001193125-22-158629-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-158629-xbrl.zip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end